Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or …
GK Bajaj, Z Zhang, E Garrett-Mayer, R Drew… - Urology, 2007 - Elsevier
OBJECTIVES: Patients with biochemical recurrence of prostate cancer after definitive or
salvage local therapy in the absence of metastatic disease represent a group well suited to a
novel therapeutic intervention. Imatinib mesylate (Gleevec) is a protein-tyrosine kinase
inhibitor that has previously been tested in men with androgen-independent and metastatic
prostate cancer. This Phase II study was undertaken to determine the safety and efficacy of
imatinib mesylate in men with biochemical relapse of nonmetastatic, androgen-sensitive …
salvage local therapy in the absence of metastatic disease represent a group well suited to a
novel therapeutic intervention. Imatinib mesylate (Gleevec) is a protein-tyrosine kinase
inhibitor that has previously been tested in men with androgen-independent and metastatic
prostate cancer. This Phase II study was undertaken to determine the safety and efficacy of
imatinib mesylate in men with biochemical relapse of nonmetastatic, androgen-sensitive …